Ifosfamide

Generic Name: Ifosfamide

Brand Names: Ifex

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 3778-73-2

Unique Ingredient Identifier: UM20QQM95Y

Background: Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication: Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.

Associated Conditions: Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma

Associated Therapies: -

Clinical Trials

PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma

Not Applicable

Completed

Conditions: Sarcoma

Interventions: Biological: pegfilgrastim
Drug: doxorubicin hydrochloride
Drug: ifosfamide
Drug: pegylated liposomal doxorubicin hydrochloride
Procedure: conventional surgery
Radiation: fludeoxyglucose F 18

First Posted Date: 2006-06-29

Last Posted Date: 2022-12-15

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 70

Registration Number: NCT00346125

Locations: 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma

Phase 3

Withdrawn

Conditions: Sarcoma

Interventions: Drug: cyclophosphamide
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: vincristine sulfate
Drug: topotecan hydrochloride
Procedure: conventional surgery
Procedure: radiation therapy

First Posted Date: 2006-06-08

Last Posted Date: 2013-06-28

Lead Sponsor: Children's Oncology Group

Registration Number: NCT00334867

Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma

Phase 3

Conditions: Childhood Malignant Fibrous Histiocytoma of Bone
Sarcoma

First Posted Date: 2006-06-08

Last Posted Date: 2013-08-12

Lead Sponsor: European Paediatric Soft Tissue Sarcoma Study Group

Target Recruit Count: 250

Registration Number: NCT00334854

Locations: 🇫🇷
Institut Curie Hopital, Paris, France
🇧🇪
Clinique de l'Esperance, Montegnee, Belgium
🇩🇰
Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark

and more 24 locations

Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Phase 2

Conditions: Lymphoma, Non-Hodgkin
Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Ondansetron
Drug: Dexamethasone
Drug: Diphenhydramine
Drug: Acetaminophen
Other: PET Scan
Drug: Ifosfamide
Drug: Mesna (IV)
Drug: Mesna (oral)
Drug: Carboplatin
Drug: Etoposide
Drug: Rituximab

First Posted Date: 2006-05-11

Last Posted Date: 2021-07-22

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 150

Registration Number: NCT00324467

Locations: 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Not Applicable

Conditions: Lymphoma

First Posted Date: 2006-04-24

Last Posted Date: 2015-09-25

Lead Sponsor: European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma

Target Recruit Count: 96

Registration Number: NCT00317408

Locations: 🇨🇿
University Hospital Brno, Brno, Czech Republic
🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇩🇪
Krankenhaus Muenchen Schwabing, Munich, Germany

and more 91 locations

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Phase 2

Completed

Conditions: Neurofibromatosis Type 1
Sarcoma

Interventions: Biological: filgrastim
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2006-03-17

Last Posted Date: 2018-09-18

Lead Sponsor: Sarcoma Alliance for Research through Collaboration

Target Recruit Count: 48

Registration Number: NCT00304083

Locations: 🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States

and more 14 locations

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Childhood Favorable Prognosis Hodgkin Lymphoma
Childhood Lymphocyte Depletion Hodgkin Lymphoma
Childhood Mixed Cellularity Hodgkin Lymphoma
Childhood Nodular Sclerosis Hodgkin Lymphoma
Stage I Childhood Hodgkin Lymphoma
Stage II Childhood Hodgkin Lymphoma

Interventions: Radiation: radiation therapy
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Drug: cyclophosphamide
Drug: ifosfamide
Drug: vinorelbine tartrate
Drug: dexamethasone
Drug: etoposide phosphate
Drug: cisplatin
Drug: cytarabine
Biological: filgrastim

First Posted Date: 2006-03-13

Last Posted Date: 2021-03-30

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 287

Registration Number: NCT00302003

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain

Phase 3

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2006-02-17

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 500

Registration Number: NCT00293358

Locations: 🇮🇪
Our Lady's Hospital for Sick Children, Dublin, Ireland
🇬🇧
Institute of Child Health at University of Bristol, Bristol, England, United Kingdom
🇬🇧
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom

and more 17 locations